BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35435496)

  • 21. Prospective Evaluation of
    Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
    Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.
    Reynolds HM; Williams S; Jackson P; Mitchell C; Hofman MS; Hicks RJ; Murphy DG; Haworth A
    BJU Int; 2019 Jun; 123(6):1020-1030. PubMed ID: 30536698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of
    Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
    Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative characterisation of clinically significant intra-prostatic cancer by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11.
    Domachevsky L; Goldberg N; Bernstine H; Nidam M; Groshar D
    Eur Radiol; 2018 Dec; 28(12):5275-5283. PubMed ID: 29846803
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Ferraro DA; Hötker AM; Becker AS; Mebert I; Laudicella R; Baltensperger A; Rupp NJ; Rueschoff JH; Müller J; Mortezavi A; Sapienza MT; Eberli D; Donati OF; Burger IA
    Eur J Hybrid Imaging; 2022 Jul; 6(1):14. PubMed ID: 35843966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of (
    Yilmaz U; Komek H; Can C; Altindag S
    Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic accuracy of
    Coşar U; Şen İ; Aydos U; Koparal MY; Uçar M; Tokgöz N; Gönül İI; Akdemir ÜÖ; Atay LÖ; Sözen TS
    Int J Clin Pract; 2021 Aug; 75(8):e14287. PubMed ID: 33931929
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer.
    Esen B; Seymen H; Gurses B; Armutlu A; Koseoglu E; Tarim K; Ertoy Baydar D; Sarikaya AF; Canda AE; Balbay D; Kordan Y; Tilki D; Esen T; Demirkol MO
    Prostate; 2024 Jan; 84(1):32-38. PubMed ID: 37661579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Accuracy of Multiparametric MRI versus
    Muehlematter UJ; Burger IA; Becker AS; Schawkat K; Hötker AM; Reiner CS; Müller J; Rupp NJ; Rüschoff JH; Eberli D; Donati OF
    Radiology; 2019 Nov; 293(2):350-358. PubMed ID: 31502937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of T staging in PI-RADS 4-5 prostate cancer by combination of multiparametric MRI and
    Ding Y; Mo C; Ding Q; Lin T; Gao J; Chen M; Lu W; Sun J; Wang F; Zang S; Zhang Q; Zhang S; Guo H
    BMC Urol; 2023 Dec; 23(1):206. PubMed ID: 38082379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer.
    Doan P; Counter W; Papa N; Sheehan-Dare G; Ho B; Lee J; Liu V; Thompson JE; Agrawal S; Roberts MJ; Buteau J; Hofman MS; Moon D; Lawrentschuk N; Murphy D; Stricker PD; Emmett L
    BJU Int; 2023 May; 131(5):588-595. PubMed ID: 36371669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study.
    Ucar T; Gunduz N; Demirci E; Culpan M; Gunel H; Kir G; Atis RG; Yildirim A
    Prostate; 2022 Nov; 82(15):1462-1468. PubMed ID: 35915579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of metastatic disease on
    Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
    BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic performance of
    Ferraro DA; Becker AS; Kranzbühler B; Mebert I; Baltensperger A; Zeimpekis KG; Grünig H; Messerli M; Rupp NJ; Rueschoff JH; Mortezavi A; Donati OF; Sapienza MT; Eberli D; Burger IA
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3315-3324. PubMed ID: 33620559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 68Ga-PSMA-11 PET/CT combining ADC value of MRI in the diagnosis of naive prostate cancer: Perspective of radiologist.
    Wang L; Yu F; Yang L; Zang S; Xue H; Yin X; Guo H; Sun H; Wang F
    Medicine (Baltimore); 2020 Sep; 99(36):e20755. PubMed ID: 32898989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot study comparing dominant intraprostatic lesion volume using Ga-68 prostate-specific membrane antigen PET-computed tomography and multiparametric MRI.
    Sasidharan A; Murthy V; Natarajan A; Agarwal A; Ranagrajan V; Gudi S; Singh S; Popat P
    Nucl Med Commun; 2020 Dec; 41(12):1291-1298. PubMed ID: 32941400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology.
    Privé BM; Israël B; Schilham MGM; Muselaers CHJ; Zámecnik P; Mulders PFA; Witjes JA; Sedelaar M; Mehra N; Verzijlbergen F; Janssen MJR; Gotthardt M; Barentsz JO; van Oort IM; Nagarajah J
    Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):423-430. PubMed ID: 32999466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection Rate of
    Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F
    Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.